Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vir Biotechnology Inc V.VIR


Primary Symbol: VIR

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.


NDAQ:VIR - Post by User

Comment by theshadow39on Mar 15, 2019 9:32pm
100 Views
Post# 29494641

RE:WOW ANNUAL STATEMENTS

RE:WOW ANNUAL STATEMENTSWeed study. 

Thanks for informing us the financials are available on sedar, here is a little snip, please everyone read the full version for yourself.  You are right, will be awesome to see what they can do with a little expansion and once they get out of the “start up” phase. 

And they really barely had their sales license, promising start !

The production cost of sales includes direct costs of $690,086, resulting in a gross profit before fair value adjustments of $81,852. The Company recognized an unrealized gain on change of fair value of biological assets of $142,620 which is the amount of cannabis plants at fair value less costs to sell up to the point of harvest during the period, resulting in a gross profit of $224,472.
<< Previous
Bullboard Posts
Next >>